跳至主要内容

Hemolysis Test

 Hemolysis test: refers to the hemolysis and red blood cell aggregation caused by pharmaceutical preparations. Hemolytic reactions include immune hemolysis and non-immune hemolysis.

1. Prepare 2% Red Blood Cells

Baoding rabbits, draw blood from the heart 5 m, add 0.2 ml of anticoagulant EDTA, wash with PBS, centrifuge to remove the white blood cells on the surface, until the supernatant does not show red, discard the supernatant, take 1 ml and add 50 ml of PBS.

2. Prepare Materials


Adjust the concentration of different kinds of materials to 800, 400, 200, 100, 50 and 25 ug/mb with PBS solution, and the concentration of gold clusters to 50, 25, 12.5, 6.25, 3.15 ug/ml.

3. Experimental Process

Before each use of red blood cells, wash with PBS until there is no obvious red (slightly yellow) in the supernatant, and draw 200ul of the substrate. Release to 10ml for use.

Mix 0.5ml of the material with 0.5ml of 2% red blood cell solution, stand still at room temperature for 3 hours, and then centrifuge at 10050 r/min for 3 minutes. Take out 100ul to 96-well plate, use 570nm wavelength to detect. Water and PBS were used as positive and negative controls, respectively. Two parallels for each sample.

Hemolysis rate (%) = (sample absorption-negative control absorption) / (positive control absorption-negative control absorption) x 100%. A hemolysis rate of more than 5% is regarded as hemolysis.

Contact Us:

Email : marketing@medicilon.com

Tel : +44 1223 981 792 (Europe)

+82 (0)70-8269-5849 (South Korea)

08044216898 (Japan)

+86 021 58591500 (China)

Website: https://www.medicilon.com

Related Articles:

Hemolysis Assay Labs

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...